Medulloblastoma/cell marker and application thereof

• Main Authors: YAO YUELIANG, BIAN XIUWU, WANG YAN
• Format: Patent
• Language: Chinese; English
• Published: 31.12.2021
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention belongs to the technical field of preparation of tumor diagnosis/prognosis reagents, and particularly relates to a medulloblastoma/cell marker and application thereof. The invention relates to the research and application of the protein in the SMO-activated mutant medulloblastoma/cell based on one or more of GPR37 protein, RAB35 protein, RPS10 protein, NUDT3 protein, USP6NL protein, REE protein, CACYBP protein and CKAP5 protein. The specific conjugates of the proteins are prepared into kits or reagents, so that the myeloblastoma/cells can be diagnosed/prognosed more simply, conveniently and accurately, and particularly, the drug-resistant myeloblastoma/cells can be screened more accurately, and then the drugs are applied according to the case. 本发明属于肿瘤诊断/预后的试剂制备技术领域，具体涉及一种髓母细胞瘤/细胞标志物及其应用。是基于GPR37蛋白、RAB35蛋白、RPS10蛋白、NUDT3蛋白、USP6NL蛋白、RERE蛋白、CACYBP蛋白、CKAP5蛋白中的一种或多种的SMO激活性突变性的髓母细胞瘤/细胞中的蛋白研究及应用。这些蛋白的特异性结合物制备成试剂盒或试剂，能更加简单、方便、精准的诊断/预后髓母细胞瘤/细胞，特别是更加精确地筛选出耐药性髓母细胞瘤/细胞，然后对症下药。